Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Shanghai Stock Exchange 603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 82.13%

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin is 82.13% for the year ending December 31, 2023, a -8.27% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 89.54%, a 4.38% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 85.78%, a 5.61% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 81.22%, a 12.73% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 72.05%, a -0.78% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

CEO	Mr. Tao Yu
IPO Date	April 29, 2020
Location	China
Headquarters	No. 31 Kexueyuan Road
Employees	3,843
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.

Key trends

Past 5 years